DNA-Aptamer Targeting Vimentin for Tumor Therapy <i>In Vivo</i>

Zamay, Tatyana N.; Kolovskaya, Olga S.; Glazyrin, Yury E.; Zamay, Galina S.; Кузнецова, Светлана А.; Spivak, E. A.; Wehbe, Mohamed; Savitskaya, Anna; Zubkova, Olga A.; Kadkina, Anastasia; Wang, Xiaoyan; Muharemagic, Darija; Dubynina, Anna; Sheina, Yuliya; Салмина, А. Б.; Berezovski, Maxim V.; Zamay, Anna S.

doi:10.1089/nat.2013.0471

Cited by 50 publications

(35 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their significant advantage is their high specificity for targets [129]. A vimentin targeting DNA aptamer NAS-24 caused apoptosis of cancer cells and reduced adenocarcinoma tumors in mice [106]. The RNA aptamer P15 was found to bind vimentin on the cell surface and specifically target pancreatic adenocarcinoma cells.…”

Section: Vimentin As a Drug Targetmentioning

confidence: 99%

Vimentin Intermediate Filaments as Potential Target for Cancer Treatment

Strouhalova

Přechová

Gandalovičová

et al. 2020

Cancers

162

143

View full text Add to dashboard Cite

Intermediate filaments constitute the third component of the cellular skeleton. Unlike actin and microtubule cytoskeletons, the intermediate filaments are composed of a wide variety of structurally related proteins showing distinct expression patterns in tissues and cell types. Changes in the expression patterns of intermediate filaments are often associated with cancer progression; in particular with phenotypes leading to increased cellular migration and invasion. In this review we will describe the role of vimentin intermediate filaments in cancer cell migration, cell adhesion structures, and metastasis formation. The potential for targeting vimentin in cancer treatment and the development of drugs targeting vimentin will be reviewed.

show abstract

Section: Vimentin As a Drug Targetmentioning

confidence: 99%

Vimentin Intermediate Filaments as Potential Target for Cancer Treatment

Strouhalova

Přechová

Gandalovičová

et al. 2020

Cancers

162

143

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated that vimentin has potential as a molecular target for anticancer therapeutics (36-38). Using different approaches, Zamay et al has also demonstrated that a selected DNA-aptamer combined with the carrier reagent arabinogalactan could target intracellular vimentin and inhibit adenocarcinoma growth in vivo (39). …”

Section: Resultsmentioning

confidence: 99%

Morph-X-Select: Morphology-Based Tissue Aptamer Selection for Ovarian Cancer Biomarker Discovery

Wang

Volk

et al. 2016

BioTechniques

View full text Add to dashboard Cite

High affinity aptamer-based biomarker discovery has the advantage of simultaneously discovering an aptamer affinity reagent and its target biomarker protein. Here, we demonstrate a morphology-based tissue aptamer selection method that enables us to use tissue sections from individual patients and identify high-affinity aptamers and their associated target proteins in a systematic and accurate way. We created a combinatorial DNA aptamer library that has been modified with thiophosphate substitutions of the phosphate ester backbone at selected 5′dA positions for enhanced nuclease resistance and targeting. Based on morphological assessment, we used image-directed laser microdissection (LMD) to dissect regions of interest bound with the thioaptamer (TA) library and further identified target proteins for the selected TAs. We have successfully identified and characterized the lead candidate TA, V5, as a vimentin-specific sequence that has shown specific binding to tumor vasculature of human ovarian tissue and human microvascular endothelial cells. This new Morph-X-Select method allows us to select high-affinity aptamers and their associated target proteins in a specific and accurate way, and could be used for personalized biomarker discovery to improve medical decision-making and to facilitate the development of targeted therapies to achieve more favorable outcomes.

show abstract

“…Identification of the proteins associated with aptamers LC-17, LC-18, and LC-224 was performed on the basis of the procedure described previously,20, 51 with some modifications described below. Here we used whole minced tumor tissues, in order to purify all tumor stroma proteins associated with the aptamers to increase the probability of the results, and, moreover, we increased the number of patients in the study with adenocarcinoma to five to seven.…”

Section: Methodsmentioning

confidence: 99%

DNA Aptamers for the Characterization of Histological Structure of Lung Adenocarcinoma

Zamay

Ivanchenko

Zamay

et al. 2017

Molecular Therapy - Nucleic Acids

Self Cite

View full text Add to dashboard Cite

Nucleic acid aptamers are becoming popular as molecular probes for identification and imaging pathology and, at the same time, as a convenient platform for targeted therapy. Recent studies have shown that aptamers may be effectively used for tumor characterization and as commercially available monoclonal antibodies. Here we present three DNA aptamers binding to whole transformed lung cancer tissues, including tumor cells, connective tissues, and blood vessels. Protein targets have been revealed using affinity purification followed by mass spectrometry analyses, and they have been validated using a panel of correspondent antibodies and 3D imaging of tumor tissues. Each of the proteins targeted by the aptamers is involved in cancer progression and most of them are crucial for lung adenocarcinoma. We propose the use of these aptamers in aptahistochemistry for the characterization of the histological structure of lung adenocarcinoma. The value of the presented aptamers is their application together or separately for indicating the spread of neoplastic transformation, for complex differential diagnostics, and for targeted therapy of the tumor itself as well as all transformed structures of the adjacent tissues. Moreover, it has been demonstrated that these aptamers could be used for intraoperative tumor visualization and margin assessment.

show abstract

DNA-Aptamer Targeting Vimentin for Tumor Therapy In Vivo

Cited by 50 publications

References 47 publications

Vimentin Intermediate Filaments as Potential Target for Cancer Treatment

Vimentin Intermediate Filaments as Potential Target for Cancer Treatment

Morph-X-Select: Morphology-Based Tissue Aptamer Selection for Ovarian Cancer Biomarker Discovery

DNA Aptamers for the Characterization of Histological Structure of Lung Adenocarcinoma

Contact Info

Product

Resources

About